核酸内切酶
化学
病毒
体内
体外
对接(动物)
生物信息学
甲型流感病毒
活动站点
病毒学
酶
病毒复制
蛋白质数据库
生物活性
正粘病毒科
结构-活动关系
生物化学
生物
基因
护理部
生物技术
医学
作者
Andrey A. Ivashchenko,Oleg D. Mitkin,Jeremy C. Jones,Alexander V. Nikitin,Angela G. Koryakova,Alexey Ryakhovskiy,Ruben N. Karapetian,Dmitry V. Kravchenko,Vladimir Aladinskiy,Irina A. Leneva,Irina N. Falynskova,Ekaterina A. Glubokova,Elena A. Govorkova,Alexandre V. Ivachtchenko
标识
DOI:10.1021/acs.jmedchem.0c00565
摘要
4-Substituted 2,4-dioxobutanoic acids inhibit influenza virus cap-dependent endonuclease (CEN) activity. Baloxavir marboxil, 4, is approved for treating influenza virus infections. We describe here the synthesis and biological evaluation of active compounds, 5a–5g, and their precursors (6a, 6b, 6d, and 6e) with flexible bulky hydrophobic groups instead of the rigid polyheterocyclic moieties. In silico docking confirmed the ability of 5a–5g to bind to the active site of influenza A CEN (PDB code: 6FS6) like baloxavir acid, 3. These novel compounds inhibited polymerase complex activity, inhibited virus replication in cells, prevented death in a lethal influenza A virus mouse challenge model, and dramatically lowered viral lung titers. 5a and 5e potently inhibited different influenza genera in vitro. Precursors 6a and 6d demonstrated impressive mouse oral bioavailability with 6a, providing effective in vivo protection. Thus, these novel compounds are potent CEN inhibitors with in vitro and in vivo activity comparable to baloxavir.
科研通智能强力驱动
Strongly Powered by AbleSci AI